on April 27, 2006
Published online before print April 27, 2006, doi: 10.1161/01.ATV.0000223866.42883.3b
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 25, 2005
Accepted on April 12, 2006
Comparative Effects of Paclitaxel and Rapamycin on Smooth Muscle Migration and Survival. Role of Akt-Dependent Signaling
Cam Patterson *;
From Carolina Cardiovascular Biology Center and Division of Cardiology (C.P., S.M., H.-H.L, N.M., E.H., R.L., P.C.), University of North Carolina, Chapel Hill, NC; Boston Scientific (R.H.), Natick, Mass.
* To whom correspondence should be addressed. E-mail: cpatters{at}med.unc.edu.
Objective--Advances in stent technology have enabled the delivery of drugs to improve outcomes after stent deployment. However, the optimal payloads for stents are not clear, and the appropriate stent-based therapies for high-risk patients, such as diabetics, have not been clearly established.
Methods and results--We used smooth muscle cell culture models to compare the activities of rapamycin and paclitaxel. Smooth muscle cells were grown in normal or high glucose to induce insulin resistance. Both paclitaxel and rapamycin activate MAP kinase pathways similarly. However, rapamycin potently activates AKT-dependent signaling, an effect that overrides the downregulation of this pathway by insulin resistance and that causes phosphorylation of the AKT-dependent transcription factor FOXO1. This effect is associated with attenuation of the anti-migratory effects of rapamycin under high glucose conditions that are not observed with paclitaxel, as well as with increased protection against ceramide-induced cytotoxicity, both of which are dependent on FOXO1 phosphorylation.
Conclusions--Differences between the ability of rapamycin and paclitaxel to activate AKT may account for their differential cell survival and antichemotactic activities. These observations may provide a basis for understanding clinical differences between rapamycin- and paclitaxel-coated stents. The approaches used in these studies can be expanded to other candidate stent payloads as a method for triage in preclinical studies.
Key words: migration • signaling • smooth muscle • stent • viability
This article has been cited by other articles:
 |
|
 |
|
  E. Mahmud, J. A. Ormiston, M. A. Turco, J. J. Popma, N. J. Weissman, C. D. O'Shaughnessy, T. Mann, J. J. Hall, T. F. McGarry, L. A. Cannon, et al. TAXUS Liberte Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus: Results From the TAXUS ATLAS Program J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 240 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chiu, D. T. Ko, P. C. Austin, E. A. Cohen, J. L. Velianou, R. Goeree, G. Blackhouse, and J. V. Tu Paclitaxel Versus Sirolimus Stents in Diabetic and Nondiabetic Patients Circ Cardiovasc Qual Outcomes, March 1, 2009; 2(2): 96 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hegner, M. Lange, A. Kusch, K. Essin, O. Sezer, E. Schulze-Lohoff, F. C. Luft, M. Gollasch, and D. Dragun mTOR Regulates Vascular Smooth Muscle Cell Differentiation From Human Bone Marrow-Derived Mesenchymal Progenitors Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 232 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2385 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Brar, J. Kim, S. K. Brar, R. Zadegan, M. Ree, I.-L. A. Liu, P. Mansukhani, V. Aharonian, R. Hyett, and A. Y.-J. Shen Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2220 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. van der Hoeven, S.-S. Liem, J. Dijkstra, S. C. Bergheanu, H. Putter, M. L. Antoni, D. E. Atsma, M. Bootsma, K. Zeppenfeld, J. W. Jukema, et al. Stent Malapposition After Sirolimus-Eluting and Bare-Metal Stent Implantation in Patients with ST-Segment Elevation Myocardial Infarction: Acute and 9-Month Intravascular Ultrasound Results of the MISSION! Intervention Study J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 192 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Mulukutla, H. A. Vlachos, O. C. Marroquin, F. Selzer, E. M. Holper, J. D. Abbott, W. K. Laskey, D. O. Williams, C. Smith, W. D. Anderson, et al. Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients A Report from the NHLBI Dynamic Registry. J. Am. Coll. Cardiol. Intv., January 1, 2008; 1: 139 - 147. [Abstract] [Full Text] [PDF]
|
|